Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SN 38 loaded biodegradable nanofiber - Cebiotex

Next Previous
Drug Profile

SN 38 loaded biodegradable nanofiber - Cebiotex

Alternative Names: CEB-01; CEB-01 PLGA Membrane - Cebiotex

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polytechnic University of Catalonia; The Sant Joan de Deu Hospital in Barcelona
  • Developer Cebiotex
  • Class Antineoplastics; Camptothecins; Indolizines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroblastoma; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for phase-I development in Soft tissue sarcoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (Implant)
  • 28 Nov 2025 CEBIOTEX completes Phase-I clinical trials in Soft tissue sarcoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (NCT04619056)
  • 06 May 2025 Phase-II clinical trials in Neuroblastoma (Recurrent, Second-line therapy or greater, In neonates, In infants, In children, In adolescents) in Spain (Implant)(NCT06986811)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top